Stevens Capital Management’s United Therapeutics UTHR Stock Holding History

Stevens Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,434	Closed	-$214K	–	436
2019 Q4	$214K	Buy	+2,434	New	+$214K	0.02%	519
2019 Q3	–	Sell	-7,451	Closed	-$582K	–	786
2019 Q2	$582K	Buy	+7,451	New	+$697K	0.03%	443
2016 Q4	–	Sell	-10,411	Closed	-$1.23M	–	1122
2016 Q3	$1.23M	Buy	+10,411	New	+$1.25M	0.05%	369
2016 Q2	–	Sell	-33,098	Closed	-$3.69M	–	1141
2016 Q1	$3.69M	Buy	+33,098	New	+$4.19M	0.15%	197
2015 Q4	–	Sell	-8,899	Closed	-$1.17M	–	1157
2015 Q3	$1.17M	Buy	8,899 +4,812	+118%	+$772K	0.05%	325
2015 Q2	$711K	Buy	+4,087	New	+$735K	0.03%	509
2015 Q1	–	Sell	-4,371	Closed	-$566K	–	1249
2014 Q4	$566K	Buy	+4,371	New	+$563K	0.02%	549
2014 Q3	–	Sell	-17,954	Closed	-$1.59M	–	1261
2014 Q2	$1.59M	Buy	17,954 +1,187	+7%	+$114K	0.04%	408
2014 Q1	$1.58M	Buy	16,767 +5,273	+46%	+$539K	0.04%	403
2013 Q4	$1.3M	Buy	+11,494	New	+$1.04M	0.04%	417

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Stevens Capital Management's UTHR Position: Q1 2020 in Review

Stevens Capital Management sold out of United Therapeutics (UTHR) in Q1 2020, closing a stake of 2,434 shares — an estimated $214K sold.

Stevens Capital Management first reported a position in UTHR in Q4 2013 and held it in 10 quarters. The position peaked at $3.69M in Q1 2016. 303 funds tracked by Wall St. Rank hold UTHR as of Q1 2020.

Stevens Capital Management reported no remaining United Therapeutics position as of Q1 2020 after selling out during the quarter.
Stevens Capital Management sold 2,434 United Therapeutics shares in Q1 2020, an estimated $214K.
Stevens Capital Management first reported a position in United Therapeutics in Q4 2013 and held it in 10 quarters.
Stevens Capital Management's United Therapeutics position peaked at $3.69M in Q1 2016.
303 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2020.

Based on Stevens Capital Management's 13F filing for Q1 2020, filed 21 Apr 2020.